Darolutamide plus hormone therapy before prostate cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a high-risk prostate cancer (Gleason score 8 or higher, PSA >20, or tumor stage T3a or higher).
- Your cancer has not spread to distant organs (confirmed by CT, MRI, or bone scan).
- You plan to have your prostate removed (radical prostatectomy) with lymph node removal.
- You are able to do normal daily activities (ECOG score 0 or 1).
- You have not taken darolutamide before and are not allergic to it or hormone therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted radioactive drug (177Lu-PSMA-617) and a hormone blocker (Darolutamide) given before surgery for high-risk prostate cancer that hasn't spread. The goal is to see if this approach can improve outcomes.
This trial tests darolutamide (a hormone blocker pill) with or without standard hormone therapy given before surgery for high-risk prostate cancer. The goal is to see if this combination can shrink the cancer and improve outcomes before the prostate is removed.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This study tests a combination of three treatments (darolutamide, docetaxel, and hormone therapy) given before surgery for men with locally advanced prostate cancer that hasn't spread. The goal is to see if this approach is safe and effective in shrinking the cancer before surgery.
Hear when a new High-Risk Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.